ArticleMedicine2022

Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report.

Hongbiao Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.